Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Page 1
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.
Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, Beebe K, Buchbinder D, Burkhard P, Carpenter PA, Chaudhri N, Elemary M, Elsawy M, Guilcher GMT, Hamad N, Karduss A, Peric Z, Purtill D, Rizzo D, Rodrigues M, Ostriz MBR, Salooja N, Schoemans H, Seber A, Sharma A, Srivastava A, Stewart SK, Baker KS, Majhail NS, Phelan R. Rotz SJ, et al. Among authors: baker ks. Bone Marrow Transplant. 2024 Feb 27. doi: 10.1038/s41409-023-02190-2. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38413823 Review.
Parallel improvements in HCT techniques and supportive care entails more patients surviving long-term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pre-, peri- and post-transplant exposures and other …
Parallel improvements in HCT techniques and supportive care entails more patients surviving long-term, creating further emphasis on s …
International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.
Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, Beebe K, Buchbinder D, Burkhard P, Carpenter PA, Chaudhri N, Elemary M, Elsawy M, Guilcher GM, Hamad N, Karduss A, Peric Z, Purtill D, Rizzo D, Rodrigues M, Ostriz MBR, Salooja N, Schoemans H, Seber A, Sharma A, Srivastava A, Stewart SK, Baker KS, Majhail NS, Phelan R. Rotz SJ, et al. Among authors: baker ks. Transplant Cell Ther. 2024 Apr;30(4):349-385. doi: 10.1016/j.jtct.2023.12.001. Epub 2024 Feb 27. Transplant Cell Ther. 2024. PMID: 38413247 Free article. Review.
Parallel improvements in HCT techniques and supportive care entails more patients surviving long term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pretransplantation, peritransplantation, and post-tr …
Parallel improvements in HCT techniques and supportive care entails more patients surviving long term, creating further emphasis on s …
Impact of Hematopoietic Cell Transplantation on Cardiovascular Risk Factors and Insulin Sensitivity.
Ketterl TG, Chow EJ, Koves IH, Goodman P, Leisenring WM, Ballard S, Dengel DR, Moran A, Sinaiko AR, Steinberger J, Baker KS. Ketterl TG, et al. Among authors: baker ks. Transplant Cell Ther. 2024 Feb;30(2):243.e1-243.e13. doi: 10.1016/j.jtct.2023.10.026. Epub 2023 Nov 5. Transplant Cell Ther. 2024. PMID: 37935316
The use of hematopoietic cell transplantation (HCT) for treating malignant conditions in children has increased over the past five decades, leading to a growing population of long-term survivors.This population of childhood HCT survivors faces increased risks of adverse me …
The use of hematopoietic cell transplantation (HCT) for treating malignant conditions in children has increased over the past five decades, …
Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Chakraborty R, Yi J, Rybicki L, Preussler J, Deol A, Loren A, Savani B, Jim HSL, Cerny J, Reynolds J, Whitten J, Wingard JR, McGuirk JP, Uberti J, Khera N, Stiff P, Jaglowski SM, Hashmi S, Holtan SG, Devine S, Hahn T, Whalen VL, Saber W, Wood W, Baker KS, Syrjala K, Majhail NS. Chakraborty R, et al. Among authors: baker ks. Transplant Cell Ther. 2023 Jun;29(6):388.e1-388.e6. doi: 10.1016/j.jtct.2023.02.011. Epub 2023 Mar 2. Transplant Cell Ther. 2023. PMID: 36870388
However, there is a paucity of data on health-related quality of life (HRQoL), distress, and health behaviors in long-term myeloma survivors who are in stable remission after autologous hematopoietic cell transplantation (AHCT). ...
However, there is a paucity of data on health-related quality of life (HRQoL), distress, and health behaviors in long-term myeloma su …
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Chow EJ, Aggarwal S, Doody DR, Aplenc R, Armenian SH, Baker KS, Bhatia S, Blythe N, Colan SD, Constine LS, Freyer DR, Kopp LM, Laverdière C, Leisenring WM, Sasaki N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE. Chow EJ, et al. Among authors: baker ks. J Clin Oncol. 2023 Apr 20;41(12):2248-2257. doi: 10.1200/JCO.22.02423. Epub 2023 Jan 20. J Clin Oncol. 2023. PMID: 36669148 Free PMC article.
PURPOSE: For survivors of childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years. However, longer-term data are lacking. METHODS: Within the Children's Oncology Group and the Dana Farber Cancer Institute's Childhood Acute Lymphoblas …
PURPOSE: For survivors of childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years. However, longer- …
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YV, Aggarwal S, Armenian SH, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE. Chow EJ, et al. Among authors: baker ks. Cancer. 2022 Feb 15;128(4):788-796. doi: 10.1002/cncr.33974. Epub 2021 Oct 13. Cancer. 2022. PMID: 34644414 Free PMC article. Clinical Trial.
BACKGROUND: The objective of this study was to examine long-term outcomes among children newly diagnosed with cancer who were treated in dexrazoxane-containing clinical trials. ...CONCLUSIONS: Dexrazoxane did not appear to adversely affect long-term mortality, event …
BACKGROUND: The objective of this study was to examine long-term outcomes among children newly diagnosed with cancer who were treated …
Accessory Genome Dynamics and Structural Variation of Shigella from Persistent Infections.
Bengtsson RJ, Dallman TJ, Allen H, De Silva PM, Stenhouse G, Pulford CV, Bennett RJ, Jenkins C, Baker KS. Bengtsson RJ, et al. Among authors: baker ks. mBio. 2021 Apr 27;12(2):e00254-21. doi: 10.1128/mBio.00254-21. mBio. 2021. PMID: 33906921 Free PMC article.
Shigellosis is a diarrheal disease caused mainly by Shigella flexneri and Shigella sonnei Infection is thought to be largely self-limiting, with short- to medium-term and serotype-specific immunity provided following clearance. ...
Shigellosis is a diarrheal disease caused mainly by Shigella flexneri and Shigella sonnei Infection is thought to be largely self-limiting, …
Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.
Phelan R, Eissa H, Becktell K, Bhatt N, Kudek M, Nuechterlein B, Pommert L, Tanaka R, Baker KS. Phelan R, et al. Among authors: baker ks. Curr Oncol Rep. 2019 Nov 25;21(12):104. doi: 10.1007/s11912-019-0861-8. Curr Oncol Rep. 2019. PMID: 31768799 Review.
RECENT FINDINGS: As new therapies emerge that are often more targeted to cancerous cells while sparing healthy tissues, the hope is that cure can be achieved without the same long-term side effects for survivors. However, much is unknown regarding how these novel intervent …
RECENT FINDINGS: As new therapies emerge that are often more targeted to cancerous cells while sparing healthy tissues, the hope is that cur …
Long-term complications in adolescent and young adult leukemia survivors.
Baker KS, Syrjala KL. Baker KS, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):146-153. doi: 10.1182/asheducation-2018.1.146. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504303 Free PMC article. Review.
Leukemia in AYAs typically presents with higher-risk biologic features, and treatment requires multiagent chemotherapy, including alkylating agents, anthracyclines, high-dose steroids, frequently intrathecal chemotherapy, and sometimes, cranial radiation. Thus, AYAs have signific …
Leukemia in AYAs typically presents with higher-risk biologic features, and treatment requires multiagent chemotherapy, including alkylating …
Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors.
Majhail NS, Murphy E, Laud P, Preussler JM, Denzen EM, Abetti B, Adams A, Besser R, Burns LJ, Cerny J, Drexler R, Hahn T, Idossa L, Jahagirdar B, Kamani N, Loren A, Mattila D, McGuirk J, Moore H, Reynolds J, Saber W, Salazar L, Schatz B, Stiff P, Wingard JR, Syrjala KL, Baker KS. Majhail NS, et al. Among authors: baker ks. Haematologica. 2019 May;104(5):1084-1092. doi: 10.3324/haematol.2018.203919. Epub 2018 Dec 4. Haematologica. 2019. PMID: 30514795 Free PMC article. Clinical Trial.
Survivorship Care Plans (SCPs) may facilitate long-term care for cancer survivors, but their effectiveness has not been established in hematopoietic cell transplantation recipients. ...SCPs were developed based on risk-factors and treatment exposures using patient data rou …
Survivorship Care Plans (SCPs) may facilitate long-term care for cancer survivors, but their effectiveness has not been established i …
78 results